Cowen Starts Corvus Pharmaceuticals (CRVS) at Outperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/11/2026

1. ORCL
2. ADBE
3. RH
4. SPY
5. CPRT
6. ACVA
7. SEDG
8. SPCX
9. TLT
10. PMTS

Go back to Cowen Starts Corvus Pharmaceuticals (CRVS) at Outperform

BTIG Starts Corvus Pharmaceuticals (CRVS) at Buy

April 19, 2016 6:47 AM EDT

BTIG initiated coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $22.00. Analyst Hartaj Singh is bullish on management and lead compound CPI-444.

"The company has two most important characteristics that we look for in early-stage biotech companies, (1)... More

Guggenheim Starts Corvus Pharmaceuticals (CRVS) at Buy

April 18, 2016 7:26 AM EDT

Guggenheim initiated coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $24.00.

For an analyst ratings summary and ratings history on Corvus Pharmaceuticals click here. For more ratings news on Corvus Pharmaceuticals click here.

Shares of Corvus Pharmaceuticals closed at $15.61 yesterday.

... More

Credit Suisse Starts Corvus Pharmaceuticals (CRVS) at Outperform

April 18, 2016 6:39 AM EDT

Credit Suisse initiates coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Outperform rating and a price target of $25.00.

Analyst V. Divan commented, "We see CRVS as a compelling earlystage immuno-oncology (I-O) opportunity that is relatively higher risk but that also offers a potentially high reward. CRVS's lead compound,... More